US equities
|
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
IsoRay, Inc. Common Stock (DE)
(NY:
ISR
)
N/A
UNCHANGED
Last Price
Updated: 8:00 PM EST, Feb 17, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about IsoRay, Inc. Common Stock (DE)
Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine
February 06, 2023
From
Isoray, Inc. and Viewpoint Molecular Targeting, Inc.
Via
Business Wire
ISORAY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Isoray, Inc - ISR
November 12, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT
October 18, 2022
From
Isoray, Inc. and Viewpoint Molecular Targeting, Inc.
Via
Business Wire
ISR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Isoray, Inc. Is Fair to Shareholders
September 29, 2022
From
Halper Sadeh LLC
Via
Business Wire
Viewpoint Molecular Targeting Announces Transformational Merger
September 29, 2022
Via
ACCESSWIRE